New device may ease restless legs without extra pills
NCT ID NCT07397247
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a noninvasive device that stimulates a nerve in the leg to help people with restless legs syndrome who have developed complications from their usual medication. About 50 adults will use the device at home for 8 weeks. Researchers will measure changes in symptom severity and sleep quality.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult 18 years of age or older when written informed consent is obtained. * Diagnosis of restless legs syndrome confirmed by IRLSSG criteria. * Moderate-severe RLS, IRLS ≥15 points at study entry * Dopaminergic augmentation based on clinician assessment and ASRS (augmentation severity rating scale) ≥5 points at study entry * Subject agrees to not change the dose or schedule of antidepressants and sleep medications. * Currently taking stable dose and schedule of dopamine agonist over the 4 weeks prior to enrollment, with average daily dose \>= 25mg Levodopa Equivalent Daily Dose (LEDD, https://pdmedcalc.co.uk/calculator). * Patient reports ≥3 nights per week in the 30d prior to study entry: waking during the sleep period with RLS symptoms that interfered with sleep re-initiation * RLS sensory symptoms in lower legs and/or feet are equally or more distressing than RLS sensory symptoms in all other anatomical locations. * The subject possesses the necessary equipment, internet/phone accessibility, and communication ability to complete electronic questionnaires and respond to electronic communications and phone calls from the research staff throughout the in-home portion of the study. * The subject has signed a valid, IRB-approved informed consent form and can understand the requirements of the study and instructions for device usage. Exclusion Criteria: * Baseline ferritin \<75 ng/mL or patient is unwilling to consider iron supplementation. * IV iron supplementation in the 6 months prior to study entry. * Change to dose of RLS prescription medication(s) in the 4 weeks prior to study entry. * Medications that are known to exacerbate RLS symptoms, including: Sedative antihistamines, Tri/tetracyclics, MAOIs, SSRIs and SNRIs, Tramadol, Neuroleptics, Antiemetics, or the anticonvulsants Phenytoin or Methsuximid * Change in medication that is known to affect RLS symptoms in the 4 weeks prior to study entry (e.g. sleep medication, antihistamines, antidepressants). * Primary sleep disorder other than RLS that significantly interferes with sleep at the time of screening visit (e.g. obstructive sleep apnea with adherent CPAP usage would not be an exclusion but typical sleep onset latency of \>60min on nights without RLS symptoms would be an exclusion). * Irregular sleep schedule: subject reports that bedtime is typically outside of 21:00 - 03:00 or reports that bedtime regularly varies by more than 4 hours, such as due to shift work. * Subject has neuropathy and is unable to clearly distinguish between symptoms of neuropathy and symptoms of RLS. * During the initial investigational device titration process, sensation threshold \>= 30mA or distraction threshold \< 15mA, or the device does not properly fit the subject. * One or more of the following confounding comorbidities: Stage 4-5 chronic kidney disease or renal failure , Iron-deficient anemia, Severe cardiac disease (NYHA class IV), Movements disorder other than RLS (Parkinson's disease, Huntington's disease, dyskinesia, dystonia), Multiple Sclerosis , Moderate-severe cognitive disorder (MoCA\<26) or mental illness, Moderate-severe edema affecting the lower legs * One or more of the following contraindications to the investigational device: Diagnosis of epilepsy or other seizure disorder, Metal implant in upper fibula, Known allergy to device materials (or severe previous reaction to medical adhesives or bandages), Open sores, or injury at or near the location of therapy device application. * Known to be pregnant or trying to become pregnant. * Medical condition not listed above that may affect validity of the study or put the subject at risk as determined by the investigator. * Subject is using another investigational device or drug during the study. * Subject does not understand the study requirements or device instructions, does not have the ability to complete the study assessments, or is unable or unwilling to comply with study requirements.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Restless legs syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Medical University of Innsbruck
Innsbruck, Tyrol, 6020, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Large survey aims to uncover hidden pain in restless legs syndrome
- Spine injection may quiet restless legs, small study hints
- New device offers Drug-Free hope for restless legs sufferers
- Botox injection shows promise for restless legs relief
- New drug candidate aims to calm restless legs when current meds backfire
- Could needling zap restless legs away?